Treating asthma

Article source Link, Article source Link,

It denies one the right to self-pay or choose the plan that suits you best. It denies the right to purchase catastrophic insurance, a true insurance plan. In our current employer-based, third-party payer system, constraints interfere with self-pay and true insurance options, but they are still options for many Americans. Under Obamacare these options will be trashed.
Do you have the right to quality care? Screenings for prostate cancer, breast cancer, colon cancer, cervical cancer are less frequent in Canada then here, explaining why cancer mortality rates are up to 25 percent higher. Fewer Canadians receive care for hypertension, asthma, diabetes and coronary heart disease than in the U.S. The U.S. has better blood pressure control than Europe, better quality of life for spinal cord injury patients than in Canada and the UK, and higher dialysis rates than the UK for the same renal disease prevalence. The U.S. has higher use of statins to lower cholesterol and higher use of anti-psychotics for treating schizophrenics.
The list goes on

Glaxo EPS before charges 25.2 pence vs consensus 24.3p Sees opportunities in credit crisis; no big buybacks in 2009 Experiencing little impact from economic slowdown on sales Shares up 2 percent, reversing earlier losses

(Adds CEO comment on strategy, analyst reaction)

By Ben Hirschler

LONDON, Oct 22 (Reuters) - GlaxoSmithKline Plc's (GSK.L: Quote, Profile, Research, Stock Buzz) earnings beat analyst forecasts on Wednesday, helped by a weak pound, and the world's second biggest drugmaker said it was hunting for acquisition bargains thrown up by the credit crunch.

The fall in sterling flattered third-quarter results from the British group due to its reliance on overseas sales, softening the blow of generic competition to several older products and a further fall in sales of diabetes pill Avandia.

Earnings per share before restructuring charges rose 6 percent to 25.2 pence on sales up 7 percent at 5.88 billion pounds. Analysts polled by Thomson Reuters had on average forecast EPS of 24.3p.

Glaxo's top-selling drug Advair -- for asthma and chronic respiratory disease -- showed good growth in the third quarter while vaccine sales were stronger than expected.

Shares in Glaxo were 2 percent higher by 1245 GMT, reversing earlier losses.

The results highlight the relative resilience of large pharmaceutical companies to the economic downturn, following better than expected figures from Pfizer Inc (PFE.N: Quote, Profile, Research, Stock Buzz) -- the global leader -- on Tuesday. Continued..

Blog Archives:
Organic polo shirt

Cutting granite tile

Holiday sweatshirt

Toddler polo shirt

Razz moped

Brass cabinet knobs

Yamaha moped parts

Tile bathroom walls

T shirts printed

Laying ceramic tile

Asthma symptoms children

Decorative cabinet hardware

Moped exhaust

Asthma infants